Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11942624 | 0.82 | CES2 (0.52) | MAPTRAB9AHDAC3HDAC4HDAC1 | |
| SCHEMBL11790422 | 0.80 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL50646 | 0.79 | MAPT (0.68) | MAPTHPGDRAB9ALMNAL3MBTL1 | |
| SCHEMBL8141436 | 0.78 | TSHR (0.60) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL9609538 | 0.77 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL799536 | 0.76 | ALDH1A1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1106586 | 0.76 | PARP10 (0.48) | MAPTLMNAL3MBTL1KMT2AHDAC3 | |
| SCHEMBL5371696 | 0.76 | MAPT (0.48) | MAPTHPGDRAB9ALMNAL3MBTL1 | |
| SCHEMBL13134721 | 0.76 | HDAC3 (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12385665 | 0.76 | KDM4E (0.47) | LMNAKMT2ASMN1; SMN2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290341-B | Urea compound with anti-tumor activity, preparation method and application | 国王医学科技(山东)有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-9732109-B2 | Pesticidal compositions | DOW AGROSCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-9468919-B2 | Ruthenium-diamine complexes and method for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-9403753-B2 | Dual site catalyst for mild, selective nitrile reduction | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160145193-A1 | DUAL SITE CATALYST FOR MILD, SELECTIVE NITRILE REDUCTION | NATIONAL SCIENCE FOUNDATION | 2016-05-26 | — | — | US | disclosed |
| US-9321045-B2 | Catalyst and process for synthesising the same | THE UNIVERSITY OF WARWICK (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2016-03-10 | — | — | US | disclosed |
| US-20090021673-A1 | Liquid Crystal Display Device | FUJIFILM CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20070290168-A1 | Resin film, production method thereof, polarizing plate and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070286998-A1 | Method of producing transparent thermoplastic film and transparent thermoplastic film | FUJIFILM CORPORATION (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070281112-A1 | Thermoplastic film and method of producing the same, polarizing plate, optical compensation film, antireflection film and liquid-crystal display device | FUJIFILM CORPORATION (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070275183-A1 | Transparent thermoplastic film and a method of producing the same | FUJIFILM CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | INMT, CROCC, GNMT | MAPT 3624/4885HPGD 3312/4885RAB9A 1851/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | MAPT 4330/4885HPGD 4250/4885RAB9A 1573/4885 |
| US-20160145193-A1 | DUAL SITE CATALYST FOR MILD, SELECTIVE NITRILE REDUCTION | KMO, FES, TDO2 | MAPT 4511/4885HPGD 3840/4885RAB9A 2901/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | MAPT 448/4885HPGD 247/4885RAB9A 2062/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | MAPT 2830/4885HPGD 333/4885RAB9A 1612/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | MAPT 4875/4885HPGD 3099/4885RAB9A 2054/4885 |
| US-20160067696-A1 | RUTHENIUM-DIAMINE COMPLEXES AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH1A, ADH1C, ADH5 | MAPT 4416/4885HPGD 2174/4885RAB9A 426/4885 |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | TLR7, TLR9, TLR1 | MAPT 2457/4885HPGD 3003/4885RAB9A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.